Dr. Mike Cusnir, MD

Dr. Cusnir practices at Mount Sinai Medical Center in Miami Beach, Florida, part of Mount Sinai Medical Center of Florida.

Dr. Cusnir's NPI, 1962490631, was assigned on October 7, 2005. Dr. Cusnir graduated from Pontifical Xavierian University in 1994. Dr. Cusnir holds Florida license ME87084.

Dr. Cusnir's primary practice is Mount Sinai Medical Center, at 4300 Alton Rd, Miami Beach, FL 33140 in Miami-Dade County. The practice phone is (305) 674-2121.

Dr. Cusnir's primary practice is Mount Sinai Medical Center in Miami Beach, Florida, part of Mount Sinai Medical Center of Florida. Dr. Cusnir is also affiliated with Sylvester Comprehensive Cancer Center. The medical group on file is Mount Sinai Medical Center. Dmand AI also links Dr. Cusnir to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cusnir practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Cusnir's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Cusnir is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Cusnir's licenses on file in 2 states: Florida and Maryland.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Cusnir treats.

CMS data shows 1,535 Medicare services from Dr. Cusnir across 6 procedure codes in 2024, for 464 Medicare patients. Medicare paid $84,602 for them.

CMS counts 464 Medicare patients who saw Dr. Cusnir in 2024. The largest group is 75 to 84, with 180 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cusnir's median patient age at 74, with 49% women.

In 2024, Dr. Cusnir wrote 2,335 Medicare Part D claims for 396 patients. 72% of them were for generic drugs. CMS names the drug for 1,853 of them, across 53 drugs with 11 or more claims each, at $6,989,141 in total drug cost. In 2023, CMS named 1,410 claims across 50 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Cusnir for performance year 2024, reported through an alternative payment model (APM). Dr. Cusnir accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cusnir as offering telehealth.

Dmand AI links 26 papers to Dr. Cusnir, published from 2011 to 2025. 2015 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor and Adenocarcinoma. Dr. Cusnir has published most often in Ann Oncol. Dr. Cusnir's most frequent co-authors are Michael Alan Schwartz, MD, Vathany Sriganeshan, MD and Kritika Krishnamurthy, MBBS.

Dmand AI links Dr. Cusnir to 4 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Adenocarcinoma Of Esophagus, Camurati-Engelmann Syndrome and Esophageal Squamous Cell Carcinoma.

CMS Open Payments shows 3,595 general payments to Dr. Cusnir from 104 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 29% of the total. Sirtex Medical Inc paid the most, $170,199.

Dmand AI lists 3 awards for Dr. Cusnir, most recently CMS Stage 1 EHR in 2013.

Dr. Cusnir graduated from Pontifical Xavierian University in 1994. Dr. Cusnir is a member of ACP, ASCO and ASH.

Dr. Cusnir is in network with 15 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.